News

The firms will evaluate the use of Advaxis’ Lm-LLO cancer immunotherapy, ADXS-PSA, in combination with Merck’s pembrolizumab in the Phase I/Phase II trial. The trial will assess the

This patent, when issued, will be valid until at least 2026. Additional patents claiming the BL-7010 composition and uses thereof are granted or pending in the US, Europe,

In the Phase 2a trial, all three doses of CCH (low (0.06mg), mid (0.48mg) and high (0.84mg)) showed an improvement in the appearance of cellulite as measured by

These patents have issued over the last several months from the intellectual property licensed by Dicerna from the City of Hope (COH) estate in November 2007. The newly

Under the new EMSA, Sucampo receives a new, lower price for certain components of or finished product of lubiprostone globally, except for the United States and Canada until

Through the program, palbociclib is being made available for use in combination with letrozole for post-menopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2

"These data are important for people suffering from moderate-to-severe plaque psoriasis, as up to 41 percent of those treated with ixekizumab were able to achieve clear skin at

Scheduled to reviewed by EMA under the centralized marketing authorization procedure, the application, if approved, would eanble the company to market isavuconazole in all 28 European Union member

Located in Wisconsin-Madison University Research Park, the 37,000ft2 sterile injectable fill finish facility will be a newly formed subsidiary of PSC Biotech, and will be named BioTechnique. The